Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
GNCAQ Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: December 30, 2022
Report Source: 2022 1st Quarter Report
Genocea Biosciences Inc. Stock Analysis GNCAQ
United States Health Care Nano Cap Report: Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Read More Genocea Biosciences Inc (GNCAQ) Chart
Financial Metrics & Statements of Genocea Biosciences Inc (GNCAQ)
FAQ's for Genocea Biosciences Inc (GNCAQ)
- According to Musaffa’s Shariah screening methodology, Genocea Biosciences Inc (GNCAQ) is currently classified as NOT HALAL as of December 2022. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Genocea Biosciences Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Genocea Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Genocea Biosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Genocea Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Genocea Biosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.